Table 2. Univariate Cox proportional analysis of clinical outcomes in 233 patients with ccRCC.

Variables	Cancer-specific survival				Overall survival				Progression-free survival
	HR	95% CI	P		HR	95% CI	P		HR	95% CI	P
Age, years (<60 vs. ≥60)	1.190	0.697–2.032	0.524		1.250	0.75–2.083	0.393		1.194	0.759–1.88	0.443
BMI, kg/m2 (<24 vs. ≥24)	1.652	0.515–5.299	0.399		1.346	0.487–3.719	0.567		1.339	0.54–3.323	0.528
Sex (male vs. female)	0.669	0.352–1.271	0.219		0.729	0.4–1.327	0.301		0.655	0.381–1.124	0.125
Size (≥5 vs. <5 cm)	4.058	1.465–11.241	0.007		2.848	1.223–6.628	0.015		2.841	1.364–5.918	0.005
Tumor stage (T3–4 vs. T1–2)	3.547	1.671–7.529	0.001		0.000	3.948–1.87	8.333		4.299	2.205–8.382	<0.001
Fuhrman stage (3–4 vs. 1–2)	3.585	1.973–6.512	<0.001		4.042	2.247–7.274	<0.001		2.914	1.8–4.718	<0.001
Lymph node (N1 vs. N0/Nx)	4.295	1.938–9.52	<0.001		3.909	1.773–8.621	0.001		3.161	1.45–6.891	0.004
Metastasis (M1 vs. M0)	5.093	2.474–10.482	<0.001		4.624	4.624–9.454	<0.001		3.918	2.004–7.662	<0.001
Sarcomatoid (yes vs. no)	3.187	1.75–5.804	<0.001		3.640	2.083–2.083	<0.001		2.726	1.599–4.647	<0.001
LVI (present vs. absent)	1.484	0.764–2.88	1.484		1.639	0.885–3.036	0.116		1.398	0.781–2.503	0.259
Necrosis (present vs. absent)	2.155	1.232–3.77	0.007		1.969	1.161–3.34	0.012		1.608	1.017–2.543	0.042
p-CREB1 staining (high vs. low)	3.322	1.566–7.046	0.002		2.274	1.205–4.293	0.011		1.686	1.001–2.84	0.050

ccRCC, clear cell renal cell carcinoma; BMI, body mass index; LVI, lymphovascular invasion.